#### Supplementary Table 1. Search strategy used for MEDLINE 1

| #  | Searches   |
|----|--|
| 1  | exp Coronavirus/   |
| 2  | exp Coronavirus Infections/  |
| 3  | exp Betacoronavirus/   |
| 4  | (coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or sudden acute respiratory syndrome*).tw,kf.   |
| 5  | (2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kf.  |
| 6  | (pneumonia.tw,kf. Or exp pneumonia/) and (Wuhan or Hubei).tw,kf.   |
| 7  | COVID-19.rx,px,ox. Or severe acute respiratory syndrome coronavirus 2.os.  |
| 8  | exp Influenza A Virus, H1N1 Subtype/   |
| 9  | ("A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 "2009") or influenza A or swine flu).tw,kf.   |
| 10 | 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9  |
| 11 | ((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or<br>endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or<br>((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or "swab<br>sample*" or "flocked swab*").tw,kf. |
| 12 | Nasal cavity/vi  |
| 13 | Sputum/vi  |
| 14 | Nasopharynx/vi   |
| 15 | Oropharynx/vi  |
| 16 | *Saliva/vi   |
| 17 | Pharynx/vi   |
| 18 | (clinical adj2 (sample* or specimen*)).tw,kf.  |
| 19 | ("RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction").tw,kf.   |
| 20 | Influenza, Human/vi  |
| 21 | exp Coronavirus Infections/vi or exp Coronavirus/vi or exp Betacoronavirus/vi  |

| 22 | polymerase chain reaction/ or multiplex polymerase chain reaction/ or real-time polymerase chain reaction/ or |
|----|---|
|    | reverse transcriptase polymerase chain reaction/  |
| 23 | 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22  |
| 24 | 10 and 23   |
| 25 | (vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kf.          |
| 26 | (((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*)).tw,kf.           |
| 27 | ((calibration adj1 curve*) or (standard adj1 curve*)).tw,kf.  |
|    | ((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2   |
| 28 | number*)).tw,kf.  |
| 29 | Viral load/   |
| 30 | Viral shedding/   |
| 31 | ("copy/m*" or "copies/m*" or "copy/test*" or "copies/test*").tw,kf.   |
| 32 | ((test or diagnos*) adj2 sensitiv*).tw,kf.  |
| 33 | 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32  |
| 34 | 24 and 33   |
| 35 | animals/ not humans/  |
| 36 | 34 not 35   |

# 3 Supplementary Table 2. Search strategy used for EMBASE

| Dat | tabase: Embase 1974 to 2020 August 06  |
|-----|--|
| #   | Searches   |
| 1   | coronavirus infection/ or severe acute respiratory syndrome/   |
| 2   | COVID 19/  |
| 3   | coronavirus disease 2019/  |
| 4   | severe acute respiratory syndrome coronavirus 2/ or SARS coronavirus 2/  |
| 5   | SARS coronavirus/ or betacoronavirus/  |
| 6   | "influenza a virus (h1n1)"/  |
| 7   | 2009 h1n1 influenza/ or "influenza a (h1n1)"/  |
| 8   | (coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or Sudden acute respiratory syndrome*).tw,kw.   |
| 9   | (2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kw.  |
| 10  | (pneumonia.tw,kw. Or exp pneumonia/) and (Wuhan or Hubei).tw,kw.   |
| 11  | (covid or SARS or H1N1 or coronavirus).ox.   |
| 12  | ("A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 "2009") or influenza A or swine flu).tw,kw.   |
| 13  | 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12  |
| 14  | nose smear/  |
| 15  | smear/ or nose smear/ or sputum smear/   |
| 16  | *sputum/   |
| 17  | *nasopharynx/ or *pharynx/   |
| 18  | throat culture/  |
| 19  | saliva analysis/   |
| 20  | *oropharynx/   |
| 21  | exp nasopharyngeal aspiration/   |
| 22  | real time polymerase chain reaction/ or real time reverse transcription polymerase chain reaction/ or reverse transcription polymerase chain reaction/   |
| 23  | (clinical adj2 (sample* or specimen*)).tw,kw.  |
| 24  | ((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or<br>endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or<br>((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or "swab<br>sample*" or "flocked swab*").tw,kw. |
| 25  | ("RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction").tw,kw.   |
| 26  | *2009 H1N1 influenza/di or coronavirus disease 2019/di or Coronavirus infection/di   |
| 27  | 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26   |

| 28 | 13 and 27  |
|----|--|
| 29 | virus load/  |
| 30 | virus shedding/  |
| 31 | (vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kw.                         |
| 32 | (((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*)).tw,kw.                          |
| 33 | ((calibration adj1 curve*) or (standard adj1 curve*)).tw,kw.   |
| 34 | ((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2 number*)).tw,kw. |
| 35 | ("copy/m*" or "copies/m*" or "copy/test*" or "copies/test*").tw,kw.  |
| 36 | ((test or diagnos*) adj2 sensitiv*).tw,kw.   |
| 37 | 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36   |
| 38 | 28 and 37  |
| 39 | exp animal/ not human/   |
| 40 | 38 not 39  |

## 5 Supplementary Table 3. Search strategy used for Cochrane Central

| Dat | tabase(s): EBM Reviews – Cochrane Central Register of Controlled Trials July 2020  |
|-----|--|
| #   | Searches   |
| 1   | exp Coronavirus/   |
| 2   | exp Coronavirus Infections/  |
| 3   | betacoronavirus/   |
| 4   | (coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or sudden acute respiratory syndrome*).tw,kw.   |
| 5   | (2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kw.  |
| 6   | (pneumonia.tw,kw. Or exp pneumonia/) and (Wuhan or Hubei).tw,kw.   |
| 7   | exp Influenza A Virus, H1N1 Subtype/   |
| 8   | ("A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 "2009") or influenza A or swine flu).tw,kw.   |
| 9   | 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8   |
| 10  | ((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or<br>endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or<br>((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or "swab<br>sample*" or "flocked swab*").tw,kw. |
| 11  | Nasal cavity/  |
| 12  | Sputum/  |
| 13  | Nasopharynx/   |
| 14  | Oropharynx/  |
| 15  | *Saliva/   |
| 16  | Pharynx/   |
| 17  | (clinical adj2 (sample* or specimen*)).tw,kw.  |
| 18  | ("RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction").tw,kw.   |
| 19  | exp Coronavirus Infections/vi or exp Coronavirus/vi or exp Betacoronavirus/vi  |
| 20  | polymerase chain reaction/ or multiplex polymerase chain reaction/ or real-time polymerase chain reaction/ or reverse transcriptase polymerase chain reaction/   |
| 21  | 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20   |
| 22  | 9 and 21   |
| 23  | (vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kw.   |
| 24  | (((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*)).tw,kw.  |
| 25  | ((calibration adj1 curve*) or (standard adj1 curve*)).tw,kw.   |
| 26  | ((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2 number*)).tw,kw.   |
| 27  | Viral load/  |

 28
 Viral shedding/

 29
 ("copy/m\*" or "copies/m\*" or "copy/test\*" or "copies/test\*").tw,kw.

 30
 ((test or diagnos\*) adj2 sensitiv\*).tw,kw.

 31
 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30

 32
 22 and 31

## 7 Supplementary Table 4. Search strategy used for Web of Science Core Collection

#### Web of Science Core Collection

| #  | Searches   |
|----|--|
| #1 | TOPIC: ((coronavirus* or "corona virus*" or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or          |
|    | HcoV* or ncov* or covid* or "sars-cov*" or sarscov* or "Sars-coronavirus*" or "Severe Acute              |
|    | Respiratory Syndrome*" or "sudden acute respiratory syndrome*" or "2019-ncov*" or 2019nCov* or           |
|    | "2019-novel CoV" or corona or ((novel or new or nouveau) NEAR/2 (CoV or Pandemi*)) OR                    |
|    | (pneumonia and (Wuhan or Hubei)) or "A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or               |
|    | pandemic) NEAR/4 "2009") or "influenza A" or "swine flu"))   |
|    | Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years                             |
| #2 | TOPIC: (((respiratory NEAR/3 (specimen* or sample* or swab*)) or sputum or nares or                      |
|    | endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) NEAR/3 (swab* or sample* or       |
|    | smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) NEAR/2 aspirat*) or              |
|    | NPA or ETA or (deep NEAR/4 saliva) or POS or "swab sample*" or "flocked swab*" or (clinical              |
|    | NEAR/2 (sample* or specimen*)) or "RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain                    |
|    | reaction"))  |
|    | Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years                             |
| #3 | TOPIC: (("vir* load*" or "vir* shed*" or "vir* burden" or "vir* titer*" or "vir* titre*" or (vir* NEAR/2 |
|    | count*) or ((copies or copy) NEAR/2 (ml or mls or milli* or microl*)) or ((RNA* or vir*) NEAR/2          |
|    | concentration*) or (calibration NEAR/1 curve*) or (standard NEAR/1 curve*) or "ct value*" or             |
|    | "cycle threshold" or ((copies or copy) NEAR/2 test*) or ((copy or copies) NEAR/2 number*) or             |
|    | "copy/m*" or "copies/m*" or "copy/test*" or "copies/test*" or ((test or diagnos*) NEAR/2                 |
|    | sensitiv*)))   |
|    | Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years                             |
| #4 | #3 AND #2 AND #1   |
|    | Refined by: [excluding] WEB OF SCIENCE CATEGORIES: (VETERINARY SCIENCES)                                 |
|    | Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years                             |

#### 9 Supplementary Table 5. Search strategy used for medRxiv and bioRxiv

#### medRxiv + bioRxiv (via Publish or Perish program)

**Keywords:** (covid OR coronavirus OR ncov OR hcov OR h1n1 OR "swine flu" OR COVID19 or SARS) AND ("copies/ml" OR "copy/ml" OR "viral load" OR "copies/test" OR "copy/test" OR "copies per ml" OR "copy per ml")

#### Publication name: MedRxiv

**Keywords:** (covid OR coronavirus OR ncov OR hcov OR h1n1 OR "swine flu" OR COVID19 or SARS) AND ("copies/ml" OR "copy/ml" OR "viral load" OR "copies/test" OR "copy/test" OR "copies per ml" OR "copy per ml")

#### Publication name: BioRxiv

### 11 Supplementary Table 6. Summary of risk of bias assessment based on the hybrid JBI

### 12 critical appraisal checklist

|  | Checklist items* |   |   |   |   |   |   |              |   |    |
|--|------------------|---|---|---|---|---|---|--------------|---|----|
| Study <sup>†</sup>                     | 1                | 2 | 3 | 4 | 5 | 6 | 7 | 8            | 9 | 10 |
| Argyropoulos et al.57                  |                  |   |   |   |   |   |   |              |   |    |
| Baggio et al.55                        |                  |   |   |   |   |   |   |              |   |    |
| Fajnzylber et al.47                    |                  |   |   |   |   |   |   |              |   |    |
| Han et al.65                           |                  |   |   |   |   |   |   |              |   |    |
| Han et al.63                           |                  |   |   |   |   |   |   |              |   |    |
| Hung et al.52                          |                  |   |   |   |   |   |   |              |   |    |
| Hurst et al.61                         |                  |   |   |   |   |   |   |              |   |    |
| lwasaki et al.53                       |                  |   |   |   |   |   |   |              |   |    |
| Kawasuji et al.66                      |                  |   |   |   |   |   |   |              |   |    |
| L'Huillier et al.62                    |                  |   |   |   |   |   |   |              |   |    |
| Lavezzo et al.43                       |                  |   |   |   |   |   |   |              |   |    |
| Lennon et al.49                        |                  |   |   |   |   |   |   |              |   |    |
| Lucas et al. <sup>56</sup>             |                  |   |   |   |   |   |   |              |   |    |
| Mitja et al.58                         |                  |   |   |   |   |   |   |              |   | 1  |
| Pan et al.64                           |                  |   |   |   |   |   |   |              |   |    |
| Peng et al.44                          |                  |   |   |   |   |   |   |              |   |    |
| Perera et al. <sup>54</sup>            |                  |   |   |   |   |   |   |              |   |    |
| Shi et al. <sup>51</sup>               |                  |   |   |   |   |   |   |              |   |    |
| Shrestha et al.50                      |                  |   |   |   |   |   |   |              |   |    |
| To et al.45                            |                  |   |   |   |   |   |   |              |   |    |
|  |                  |   |   |   |   |   |   |              |   |    |
| van Kampen et al.35<br>Vetter et al.59 |                  |   |   |   |   |   |   |              |   |    |
|  |                  |   |   |   |   |   |   |              |   |    |
| Wölfel et al. <sup>13</sup>            |                  |   |   |   |   |   |   |              |   |    |
| Xu et al. <sup>60</sup>                |                  |   |   |   |   |   |   |              | - |    |
| Zhang et al.42                         |                  |   |   |   |   |   |   |              |   |    |
| Zheng et al.48                         |                  |   |   |   |   |   |   |              |   |    |
| Zou et al.46                           |                  |   |   |   |   |   |   |              |   |    |
| Chen et al.69                          |                  |   |   |   |   |   |   |              |   |    |
| Chu et al.67                           |                  |   |   |   |   |   |   |              |   |    |
| Chu et al.70                           |                  |   |   |   |   |   |   |              |   |    |
| Chu et al. <sup>72</sup>               |                  |   |   |   |   |   |   |              |   |    |
| Cheng et al.74                         |                  |   |   |   |   |   |   |              |   |    |
| Hung et al. <sup>73</sup>              |                  |   |   |   |   |   |   |              |   |    |
| Peiris et al.75                        |                  |   |   |   |   |   |   |              |   |    |
| Poon et al.68                          |                  |   |   |   |   |   |   |              |   |    |
| Poon et al. <sup>71</sup>              |                  |   |   |   |   |   |   |              |   |    |
| Alves et al.98                         |                  |   |   |   |   |   |   |              |   |    |
| Chan et al.88                          |                  |   |   |   |   |   |   |              |   |    |
| Cheng et al.99                         |                  |   |   |   |   |   |   |              |   |    |
| Cowling et al.96                       |                  |   |   |   |   |   |   |              |   |    |
| Duchamp et al. <sup>101</sup>          |                  |   |   |   |   |   |   |              |   |    |
| Esposito et al.94                      |                  |   |   |   |   |   |   |              |   |    |
| Hung et al.89                          |                  |   |   |   |   |   |   |              |   |    |
| lp et al. <sup>80</sup>                |                  |   |   |   |   |   |   |              |   |    |
| Ito et al. <sup>92</sup>               |                  |   |   |   |   |   |   |              |   |    |
| Killingley et al.86                    |                  |   |   |   |   |   |   |              |   |    |
| Launes et al. <sup>85</sup>            |                  |   |   |   |   |   |   |              |   |    |
| Lee et al. <sup>87</sup>               |                  |   |   |   |   |   |   |              |   |    |
| Lee et al. <sup>95</sup>               |                  |   |   |   |   |   |   |              |   |    |
| Li et al. <sup>78</sup>                |                  |   |   |   |   |   |   |              |   |    |
| Li et al. <sup>93</sup>                |                  |   |   |   |   |   |   |              |   |    |
| Loeb et al. <sup>76</sup>              |                  |   |   |   |   |   |   |              |   |    |
| Lu et al. <sup>79</sup>                |                  |   |   |   |   |   |   |              |   |    |
| Meschi et al.82                        |                  |   |   |   |   |   |   |              |   |    |
| Ngaosuwankul et al. <sup>100</sup>     |                  |   |   |   |   |   |   |              |   |    |
| Rath et al. <sup>81</sup>              |                  |   |   |   |   |   |   |              |   |    |
| Suess et al. <sup>77</sup>             |                  |   |   |   |   |   |   |              |   |    |
|  |                  |   |   |   |   |   |   |              |   |    |
| Thai et al. <sup>91</sup>              |                  |   |   |   |   |   |   |              |   |    |
| To et al. <sup>90</sup>                |                  |   |   |   |   |   |   |              |   |    |
| To et al.97                            |                  |   |   |   |   |   |   |              |   |    |
| Watanabe et al. <sup>102</sup>         |                  |   |   |   |   |   |   |              |   |    |
| Wu et al.83                            |                  |   |   |   |   |   |   |              |   |    |
| Yang et al.84                          |                  |   |   |   |   |   |   | ). Green, ve |   |    |

<sup>13</sup> 14 15

\*Descriptions of each item are included in the hybrid JBI critical appraisal checklist (shown in Supplementary Notes). Green, yellow and red represent yes, unclear and no, respectively. \*References 13 and 35 are listed in the main body while those 42 and after are listed in Methods.

# 16 Supplementary Notes. Hybrid JBI critical appraisal checklist

| Auth | nor   | Year   | Record Number |           |                   |
|------|---|--------|---------------|-----------|-------------------|
|      |   | Yes    | No            | Unclear   | Not<br>applicable |
| 1.   | Was the sample frame appropriate to address the target population?  |        |               |           |                   |
| 2.   | Were the study subjects and the setting described in detail?  |        |               |           |                   |
| 3.   | Did the study have consecutive inclusion of<br>participants for case series and cohort studies?<br>Did the study use probability-based sampling<br>for cross-sectional studies? | ?<br>□ |               |           |                   |
| 4.   | Was the response rate adequate, and if not,<br>was the low response rate managed<br>appropriately?  |        |               |           |                   |
| 5.   | Was the sample size adequate?   |        |               |           |                   |
| 6.   | Were valid methods used for the identification of the condition?  |        |               |           |                   |
| 7.   | Were standard, valid methods used for measurement of the exposure?  |        |               |           |                   |
| 8.   | Was the exposure measured in an objective, reliable way for all participants  |        |               |           |                   |
| 9.   | Was there clear reporting of clinical information of the participants?  |        |               |           |                   |
| 10.  | Was statistical analysis appropriate?   |        |               |           |                   |
|      | rall appraisal: Include  Exclude Exclude Exclude Excluding reason for exclusion)  | See    | ek furth      | er info 🗌 | ]                 |

## 26 Tool Guidance

27 Answers: Yes, No, Unclear or Not/Applicable

28 This hybrid checklist was based on the JBI Critical Appraisal Checklists for case series, prevalence

29 studies and analytical cross-sectional studies.

30

### 31 1. Was the sample frame appropriate to address the target population?

# 32 This question relies upon knowledge of the broader characteristics of the population of33 interest and the geographical area.

This study broadly investigates the respiratory viral load for the diseases of interest. The population of interest is the general population infected with SARS-CoV-2, SARS-CoV-1, or A(H1N1)pdm09. The geographical area is not constrained. Sample frames restricted to particular subgroups within the general infected population were considered appropriate if they targeted one of the following groups analysed in our study: asymptomatic, presymptomatic, symptomatic, adult, pediatric, hospitalized, non-hospitalized, or community.

41

#### 42 2. Were the study subjects and the setting described in detail?

- 43 Certain diseases or conditions vary in prevalence across different geographic regions and
  44 populations (e.g. Women vs. Men, sociodemographic variables between countries). The
  45 study sample should be described in sufficient detail so that other researchers can
  46 determine if it is comparable to the population of interest to them
- 47

# 48 48 48 49 49 49 49 49 49 40 40 41 41 42 43 44 <

50 Inclusion of consecutive participants for case series and cohort studies yields results at 51 lower risk of bias compared to other sampling methods for these study designs. Use of 52 probability-based sampling methods for cross-sectional studies yields estimates at lower 53 risk of bias compared to other sampling methods for this design. Studies that indicate a 54 consecutive inclusion are more reliable than those that do not. For example, a case series 55 that states 'we included all patients (24) with osteosarcoma who presented to our clinic 56 between March 2005 and June 2006' is more reliable than a study that simply states 'we 57 report a case series of 24 people with osteosarcoma.'

58

# 594.Was the response rate adequate, and if not, was the low response rate managed60appropriately?

- 61 A large number of dropouts, refusals or "not founds" amongst selected subjects may 62 diminish a study's validity, as can a low response rates for survey studies. The authors 63 should clearly discuss the response rate and any reasons for non-response and compare 64 persons in the study to those not in the study, particularly with regards to their socio-65 demographic characteristics. If reasons for non-response appear to be unrelated to the 66 outcome measured and the characteristics of non-responders are comparable to those 67 who do respond in the study, the researchers may be able to justify a more modest 68 response rate.
- 69

71

72

73

74

#### 5. Was the sample size adequate?

The larger the sample, the narrower will be the confidence interval around the prevalence estimate, making the results more precise. An adequate sample size is important to ensure good precision of the final estimate. The sample size threshold was calculated as follows:

 $n^* = \frac{z^2\sigma}{d^2}$ 

75where  $n^*$  is the sample size threshold, z is the z-score for the level of confidence (95%),  $\sigma$ 76is the standard deviation (assumed to be 3 log10 copies/ml, a fourth of the full range of77rVLs) and d is the marginal error (assumed to be 1 log10 copies/ml, based on the minimum78detection limit for qRT-PCR across studies). This item was met if  $\geq$ 75% of the included DFSO79had  $\geq$ 46 specimen measurements.

80

82

83

84

85

86

87

88

#### 81 6. Were valid methods used for the identification of the condition?

Many health problems are not easily diagnosed or defined and some measures may not be capable of including or excluding appropriate levels or stages of the health problem. If the outcomes were assessed based on existing definitions or diagnostic criteria, then the answer to this question is likely to be yes. If the outcomes were assessed using observer reported, or self-reported scales, the risk of over- or under-reporting is increased, and objectivity is compromised. Importantly, determine if the measurement tools used were validated instruments as this has a significant impact on outcome assessment validity.

89

90

#### 7. Were standard, valid methods used for measurement of the exposure?

- 91The study should clearly describe the method of measurement of exposure. Assessing92validity requires that a 'gold standard' is available to which the measure can be93compared. The validity of exposure measurement usually relates to whether a current94measure is appropriate or whether a measure of past exposure is needed.
- 95 In this study, standard methods to measure viral load in respiratory specimens are RT96 PCR quantifying via one of the standard genes for each virus.

### 8. Was the exposure measured in an objective, reliable way for all participants?

- 99 The study should clearly describe the procedural aspects of the measurement of 100 exposure as well as factors that can contribute to heterogeneity in measurement.
- 101In this study, objective, reliable interpretation of the exposure depends on the use of102quantitative calibration; the specification of extraction; determination of the viral load as103a standard metric (e.g., copies/ml or equivalent) or in a manner that can be converted to104a standard metric; and, if present, specification of the amount of diluent (e.g., viral105transport media) used.
- 106

### 107 9. Was there clear reporting of clinical information of the participants?

- 108There should be clear reporting of clinical information of the participants such as the109following information where relevant: disease status, comorbidities, stage of disease,110previous interventions/treatment, results of diagnostic tests, etc.
- 111 In addition, there should be clear reporting of the number and types (asymptomatic,
- 112 presymptomatic, symptomatic, adult, pediatric, hospitalized, non-hospitalized,
- 113 community, etc.) of cases for measurements within the sampling periods of interest. For
- 114 studies that include data outside of the infectious period, there should be clear reporting
- 115of clinical information for participants for the specimen measurements that were116collected from within the infectious period.
- 117

#### 118 10. Was statistical analysis appropriate?

119As with any consideration of statistical analysis, consideration should be given to whether120there was a more appropriate alternate statistical method that could have been used.121The methods section of studies should be detailed enough for reviewers to identify which122analytical techniques were used and whether these were suitable.